This same study also concluded that the combined presence of autoantibodies against cyclin B1, Survivin, p53, RalA, DFS70/LEDGFp75, MDM2, and NPM1 could discriminate between PC patients and healthy controls with 80.5% sensitivity and 91% specificity, although follow-up studies are needed to verify its diagnostic value. Here, CCNB1 is linked to pachyonychia congenita.